Search results
Results from the WOW.Com Content Network
Biguanide (/ b aɪ ˈ ɡ w ɒ n aɪ d /) is the organic compound with the formula HN(C(NH)NH 2) 2. It is a colorless solid that dissolves in water to give a highly basic solution. It is a colorless solid that dissolves in water to give a highly basic solution.
Pioglitazone/metformin is indicated as an adjunct to diet and exercise: [medical citation needed] To improve glycemic control in patients with type 2 diabetes, or; For patients who are already treated with a separate combination of pioglitazone and metformin, For patients whose diabetes is not adequately controlled with metformin alone, or
Biguanides reduce hepatic glucose output and increase uptake of glucose by the periphery, including skeletal muscle. Although it must be used with caution in patients with impaired liver or kidney function, Metformin, a biguanide, has become the most commonly used agent for type 2 diabetes in children and teenagers. Among common diabetic drugs ...
Vildagliptin/metformin is indicated in the treatment of type-2 diabetes mellitus: [4] [6] [7] it is indicated in the treatment of adults who are unable to achieve sufficient glycaemic control at their maximally tolerated dose of oral metformin alone or who are already treated with the combination of vildagliptin and metformin as separate tablets.
Exenatide is used to treat type 2 diabetes as an add-on to metformin, a biguanide, or a combination of metformin and a sulfonylurea, or thiazolidinediones such as pioglitazone. [ 2 ] [ 3 ] A 2011 Cochrane review showed a HbA1c reduction of 0.20% more with Exenatide 2 mg compared to insulin glargine , exenatide 10 μg twice daily, sitagliptin ...
It was found that Acarbose appeared to reduce incidence of diabetes mellitus type 2 when compared to placebo, however there was no conclusive evidence that acarbose compare to diet and exercise, metformin, placebo, no intervention improved all-cause mortality, reducer or increased risk of cardiovascular mortality, serious or non-serious adverse ...
Main page; Contents; Current events; Random article; About Wikipedia; Contact us; Pages for logged out editors learn more
This page was last edited on 3 November 2024, at 11:47 (UTC).; Text is available under the Creative Commons Attribution-ShareAlike 4.0 License; additional terms may apply.